Since CD44 contributes much to BCICs' maintenance and activity as its surface marker and BCICs play an important role in breast cancer tumorigenesis, it is inferable that the possible quantitative change of CD44 caused by rs13347 C/T mutation will affect breast cancer development, especially in ER-negative patients. Here, ESR1 is linked to breast carcinoma.